How to go Paperless in an FDA-Regulated Environment using Electronic Workflow Signature Approvals and Electronic Records
About the Course
Operating in a paperless environment under FDA oversight requires more than adopting software — it demands a structured approach to security, access controls, signature authentication, and audit readiness. 21 CFR Part 11 defines specific requirements for electronic records and electronic signatures, and gaps in implementation carry direct regulatory consequences. Organizations that proceed without a validated, compliant framework risk audit findings, system failures, and costly remediation.
This course addresses the full scope of ER/ES implementation: from evaluating readiness and conducting cost-benefit analysis, to managing organizational change, defining roles, and integrating electronic signature capability into existing applications. It also prepares professionals for FDA audits targeting these systems, covering what inspectors look for and how compliant workflows should be documented and defended.
Key Areas Covered
Quality training, expert insights, and answers that matter. Know your Expert
Commonly Asked Questions About This Subject
What causes electronic records and electronic signature systems to fail FDA inspection despite having validation documentation?
FDA inspection concerns often arise when validation documentation exists but the company cannot demonstrate that the system remains controlled during routine operation. Inspectors frequently move beyond the original validation package and examine how the system is managed after implementation.
A recurring issue is that teams complete validation activities but do not maintain the same level of discipline when changes occur. User roles may expand, workflows may be modified, configurations may change, or system issues may be handled without a clear assessment of impact.
During inspections, questions often focus on ownership and decision-making. Reviewers want to understand who evaluated risks, who approved changes, and how the company determined that the validated state was maintained.
A system becomes difficult to defend when records show that implementation was completed but provide limited evidence of ongoing control. The strongest evidence connects validation decisions, operational use, change management, and oversight activities into a clear history of control.
How should companies determine whether an electronic workflow is compliant when replacing paper approvals?
Replacing paper approvals with electronic workflows requires careful evaluation of whether the process still maintains appropriate control over review, approval, accountability, and record integrity. The software capability alone does not determine whether the workflow is defensible.
A frequent problem occurs when teams configure workflows based on existing business practices without examining whether the approval sequence still reflects the intended quality decision process. Inspectors may question whether a signature represents meaningful review or simply a digital version of a manual step.
Workflow decisions become difficult to defend when responsibilities, approval meaning, and escalation paths are unclear. Problems often appear when business users assume the system configuration automatically provides the required controls.
A well-controlled workflow has documented decisions behind its design. The evidence that carries weight shows why approvals occur at specific points, who is responsible for each decision, and how the electronic process supports the intended control strategy.
Which documentation weaknesses create the greatest FDA inspection concerns for electronic records and signatures?
Documentation weaknesses involving access decisions, system changes, and record management frequently create inspection concerns because they affect whether the company can demonstrate control over electronic information. A functioning system does not eliminate the need to explain how control decisions were made.
One recurring issue involves user access management. Inspectors often ask why individuals received specific permissions, who approved those permissions, and whether access remained appropriate after responsibilities changed.
Change documentation is another area where problems develop. A system update may appear routine, but missing impact assessments or unclear approval rationale can raise questions about whether the validated state was preserved.
The strongest documentation demonstrates accountability rather than simply recording activity. Reviewers need to see who made decisions, what information supported those decisions, and how risks were evaluated. Electronic records systems become harder to defend when documentation shows completed tasks but not the reasoning behind them.
How can companies avoid compliance problems when business priorities push for faster paperless implementation?
Compliance problems often develop when implementation timelines move ahead of decisions about ownership, workflow controls, and system responsibilities. Teams may successfully deploy technology but later discover that important control decisions were never clearly defined.
A practical issue seen during reviews is that business users, IT teams, validation groups, and quality functions may each assume another group owns specific decisions. This creates gaps when questions arise about workflow logic, access controls, system changes, or record reliability.
Implementation choices become difficult to defend when compliance considerations are added after configuration decisions have already been made. Late changes often create additional validation work, documentation gaps, and operational disruption.
A controlled implementation establishes accountability before system use begins. The strongest evidence shows that responsible groups evaluated risks, agreed on control expectations, and maintained oversight throughout the system lifecycle rather than treating compliance as a final review step.
Ready to Strengthen Your Team? Let’s Build Your Training Plan.
Your team deserves the clarity.
Your organization deserves the confidence.
Upcoming Courses
Your TalkFDA Webinar Experience
1. Confirmation
3. Access course materials
4. Watch The Streaming and Complete your Course


